• GDC-0068 (RG7440): Evidence and Research Context

  2026-10-10

  GDC-0068, also known as RG7440, is a supplier-described pan-AKT, ATP-competitive research compound used to study PI3K/Akt/mTOR signaling. This overview separates supplier claims from peer-reviewed evidence and explains why global Akt inhibition should not be treated as a spatially selective test of nuclear mTORC1.

• Nuclear mTORC1 Functions Revealed by TerminaTOR

  2026-10-09

  The reference study introduces TerminaTOR, a genetically encodable inhibitor that selectively perturbs mTORC1 in defined subcellular compartments. Its findings indicate that nuclear mTORC1 has transcriptional functions distinct from canonical lysosomal signaling, especially at genes containing CCAAT motifs.

• DiscoveryProbe Metabolism-related Compound Library

  2026-10-09

  Explore how the DiscoveryProbe Metabolism-related Compound Library can support a rigorous transition from clinical metabolomic signatures to testable metabolic mechanisms. This article interprets propranolol-related burn research, evidence boundaries, and conceptual applications in enzyme, lipid, receptor, and cancer metabolism studies.

• DiscoveryProbe Bioactive Compound Library Plus

  2026-10-08

  The DiscoveryProbe Bioactive Compound Library Plus is best understood as a hypothesis-generating perturbation panel, not a catalogue of proven target interactions. This article connects its broad pathway coverage with thermal-shift evidence, orthogonal validation, and the interpretive limits described in recent bacterial ligand-screening research.

• Carfilzomib (PR-171): Evidence and Research Context

  2026-10-08

  A source-grounded overview of Carfilzomib (PR-171), covering its proteasome-targeting rationale, relevance to multiple myeloma research, connections to PDI and HDAC inhibitor studies, and the limits of current evidence.

• SUMO Protease (Ulp): Product Overview

  2026-10-07

  SUMO Protease (Ulp), SKU K1103, is an APExBIO-listed recombinant Ulp1 protease described for conceptual SUMO fusion tag cleavage. No matched research paper is available, so performance claims remain supplier-reported and un independently validated.

• SUMO Protease (Ulp) Product Overview

  2026-10-07

  Supplier-documented overview of APExBIO SUMO Protease (Ulp), including its identity, conceptual role in SUMO tag removal, and evidence limitations.

• Deferasirox, Ferritinophagy, and Lysosomal Stress

  2026-10-06

  A source-grounded overview of deferasirox as an oral iron chelator and its conceptual relevance to the 2025 TCF25–lysosomal stress study. The evidence supports a research hypothesis linking iron availability with nutrient-stress responses, but does not establish that deferasirox regulates TCF25, ferritinophagy, or lysosome-dependent cell death.

• Fluorescein Tyramide in Neurobehavioral Research

  2026-10-06

  Fluorescein Tyramide is a fluorescent labeling dye used conceptually for amplified molecular detection in imaging and cell-analysis workflows. This overview separates supplier-described applications from findings in a 2026 mouse study of early life adversity, oxytocin signaling, and looming-evoked defensive behavior, while outlining evidence strength, limitations, and translational boundaries.

• Zoledronic Acid: Evidence, Principles, and Limits

  2026-10-05

  A source-grounded overview of Zoledronic Acid as a nitrogen-containing bisphosphonate, examining its proposed biological principles, the quality of available evidence, interpretation of cancer-cell and bone findings, and the limits of extrapolating catalogue descriptions or unrelated mechanistic studies to clinical conclusions.

• α-Linolenic Acid: Evidence, Scope, and Limits

  2026-10-05

  A source-grounded overview of α-linolenic acid, distinguishing established lipid-metabolism principles from evidence about arachidonic acid and vaccine-related immunity.

• Otilonium Bromide: From Target to Evidence

  2026-10-04

  Otilonium Bromide is an antimuscarinic agent for studying cholinergic signaling, smooth muscle physiology, and neuroscience receptor modulation. This article adds an evidence-focused framework for separating receptor pharmacology from computational antiviral claims and for interpreting translational relevance without overstating the data.

• ICG001 and Wnt/β-Catenin Research Context

  2026-10-03

  A source-grounded overview of ICG001 as a research tool for studying CBP/β-catenin transcription, with emphasis on how it may conceptually clarify lithium-enhanced osteogenesis, exosomal Wnt10a signaling, cancer models, and fibrosis research while distinguishing direct evidence from supplier-reported claims.

• Nipah Virus Polymerase Complex: Structural Insights

  2026-10-01

  The reference study resolves the Nipah virus L–P polymerase complex at 2.5 Å and the connecting domain at 1.85 Å, defining how the catalytic L protein is organized and how tetrameric P engages the polymerase. These structures clarify the roles of the RdRp, PRNTase, and metal-binding features while providing a framework for structure-guided Nipah virus antiviral research.

• Baicalein: From 12-LOX Biology to Translation

  2026-10-01

  A translational perspective on Baicalein as a 12-LOX-centered research tool, connecting arachidonic acid metabolism, apoptosis, inflammation, cancer-cell phenotypes, and chemotherapy-neurotoxicity study design.

7963 records 1/531 page Next 12345 下5页 Last page